| Identification | Back Directory | [Name]
4H,5H-Pyrano[3,2-c][1]benzopyran-3-carbonitrile, 2-amino-4-[4-(6-fluoro-5-methyl-3-pyridinyl)phenyl]-5-oxo- | [CAS]
2254434-33-6 | [Synonyms]
4H,5H-Pyrano[3,2-c][1]benzopyran-3-carbonitrile, 2-amino-4-[4-(6-fluoro-5-methyl-3-pyridinyl)phenyl]-5-oxo- | [Molecular Formula]
C25H16FN3O3 | [MOL File]
2254434-33-6.mol | [Molecular Weight]
425.41 |
| Chemical Properties | Back Directory | [Boiling point ]
727.8±60.0 °C(Predicted) | [density ]
1.46±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
3.05±0.40(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
AMPC is a potent and effective TFF3 inhibitor. AMPC inhibits cell proliferation, survival, oncogenicity, and CSC-like behaviour in TFF3-positive CMS4 CRC cells. AMPC acts as a potential anti-cancer agent alone or in combination with 5-FU, and can be used for cancer research[1]. | [in vivo]
AMPC (intraperitoneal injection; 40 mg/kg; once daily) leads to a significant reduction of tumour volume in AMPC-treated mice as compared to vehicle-treated mice from day 11 onward. AMPC results in larger areas of tumour necrosis and increased area of cells with apoptotic features in SW620 tumours. AMPC also significantly reduces tumour and serum TFF3 levels in vivo. | Animal Model: | SW620 cells are subcutaneously injected into nude mice[1] | | Dosage: | 40 mg/kg | | Administration: | Intraperitoneal injection; 40 mg/kg; once daily | | Result: | Lead to tumor decreasein vivo.
Results in a marked reduction of Ki67 expression in tumor. |
| [References]
[1] Ru-Mei Chen, et al. Pharmacological Inhibition of TFF3 Enhances Sensitivity of CMS4 Colorectal Carcinoma to 5-Fluorouracil through Inhibition of p44/42 MAPK. Int J Mol Sci. 2019 Dec 9;20(24):6215 DOI:10.3390/ijms20246215 |
|
|